Drug intelligence / Profile preview

pt-bocrot

Development stage: Preclinical
Lead developer: University of Cincinnati
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Administration: In Vitro (experimental)

Overview

Pt-BocRot is a platinum-containing rotaxane compound designed as a cytotoxic agent, specifically explored for anticancer activity. It is a type of "host-rotaxane" molecule in which platinum (Pt) is chemically linked to a rotaxane scaffold featuring a Boc (tert-butyloxycarbonyl) protecting group. The compound was assessed for cytotoxic activity in cancer cell lines, particularly ovarian cancer cells resistant to cisplatin, and demonstrated significant cytotoxicity through an apoptotic mechanism. This structure is distinguished from related compounds such as Pt-ArgRot, which uses arginine moieties instead of the Boc group[6].

Other names: Pt-BocRot

Targets

3WJ (Y-shaped DNA junction)

Beyond the preview

Go deeper on pt-bocrot.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pt-bocrot.

Explore the full profile